| Literature DB >> 18044141 |
Elizabeth Bass1, Etienne Pracht, Philip Foulis.
Abstract
GOALS: Recent findings suggest the prevalence of osteoporosis among men is under-recognized. The patient population of the Veterans Health Administration (VA) is predominantly male and many elderly veterans may be at risk of osteoporosis. Given the lack of data on male osteoporosis, we provide initial insight into diagnostic procedures for patients at one VA medical center. PROCEDURES: A review and descriptive analysis of patients undergoing radiological evaluation for osteoporosis at one VA medical center.Entities:
Mesh:
Year: 2007 PMID: 18044141 PMCID: PMC2684511
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
General risk factors for osteoporosis in men
| 1. | Personal history of fracture after age 50 |
| 2. | History of fracture in a 1st degree relative |
| 3. | Current low bone mass |
| 4. | Being thin and having a small frame, or both |
| 5. | Advanced age |
| 6. | A family history of osteoporosis |
| 7. | Low lifetime calcium intake |
| 8. | Vitamin D deficiency |
| 9. | Use of certain medications (corticosteroids, chemotherapy, anticonvulsants and others) |
| 10. | Presence of certain chronic medical conditions |
| 11. | Low testosterone levels in men |
| 12. | An inactive lifestyle |
| 13. | Current cigarette smoking |
| 14. | Excessive use of alcohol |
| 15. | Being Caucasian or Asian, although African Americans and Hispanic Americans are at significant risk as well |
Adapted with permission as excerpt from http://www.nof.org/osteoporosis/diseasefacts.htm,
The National Osteoporosis Foundation, Washington DC 2007. All rights reserved.
Annual scan procedures (CPT codes) by gender
| CT Bone Density, Axial (76070) | 47 (8) | 83 (9) | 187 (19) | 326 (26) |
| DXA, Axial (76075) | 493 (86) | 806 (89) | 760 (77) | 912 (72) |
| DXA, Appendicular (peripheral) (76076) | 32 (6) | 34 (3) | 32 (3) | |
| Total | 572 | 907 | 981 | 1,270 |
| Change from previous year | 59% | 8% | 29% | |
| CT Bone Density, Axial (76070) | 47 (5) | 52 (7) | 70 (10) | 130 (20) |
| DXA, Axial (76075) | 896 (93) | 641 (91) | 606 (86) | 502 (78) |
| DXA, Appendicular (peripheral) | ||||
| (76076) | (2) | (2) | (4) | (2) |
| Total | 960 | 708 | 701 | 644 |
| Change from previous year | –26% | –1% | –8% | |
| 1,532 | 1,615 | 1,682 | 1,914 | |
| Percent male | 37% | 56% | 58% | 66% |
Note: *Percentages may not equal 100 due to rounding; n = 6,743;
The exact number (and percent) less than 30 not reported; sourced from VistA with calculations by the authors.
Abbreviations: CPT, common procedure terminology; CT, computed tomography; DXA, dual-energy X-ray absorptiometry, FY, financial year.
Figure 1Bone mineral density scans for males, 2001–2004.
Note: n = 3,730; sourced from VistA with calculations by the authors.
Abbreviations: CT, computed tomography; DXA, dual-energy X-ray absorptiometry, FY, financial year.
Age distribution (percentages)* by gender of scan recipients by first and last year of study, including four year annual average
| under 40 | 3.3 | 2.8 | 2.1 | 2.5 | 2.7 |
| 40–49 | 8.9 | 9.1 | 7.85 | 7.4 | 8.3 |
| 50–59 | 22.9 | 21.1 | 21.4 | 19.5 | 21.2 |
| 60–69 | 25.7 | 23.5 | 24.9 | 21.7 | 23.9 |
| 70–79 | 28.9 | 29.2 | 31.0 | 31.2 | 30.1 |
| 80 and over | 10.3 | 14.3 | 12.7 | 17.7 | 13.8 |
| Sample size | 572 | 907 | 981 | 1,270 | |
| under 40 | 2.0 | 1.55 | 2 | 2.8 | 2.1 |
| 40–49 | 13.2 | 19.9 | 17.4 | 17.7 | 17.1 |
| 50–59 | 33.2 | 33.9 | 35.5 | 42.4 | 36.3 |
| 60–69 | 25.7 | 21.9 | 21.7 | 19.7 | 22.3 |
| 70–79 | 17.7 | 15.7 | 14.3 | 8.9 | 14.1 |
| 80 and over | 8.1 | 7.1 | 9.1 | 8.5 | 8.2 |
| Sample size | 960 | 708 | 701 | 644 | |
Note: *Percentages may not equal 100 due to rounding; sourced from VistA with calculations by the authors.
Abbreviations: FY, financial year.
Figure 2Trends for male scan recipients by age, 2001–2004.
Note: sourced from VistA with calculations from the authors.
Abbreviations: FY, financial year.
Scan patients (%)* receiving drugs with potential bone-loss side effects 2001–2004
| Steroids | 36% | 26% |
| Anticonvulsants | 30% | 21% |
| | 26% | 19% |
| | 8% | 4% |
| Thyroid | 10% | 22% |
| Methotrexate | 7% | 3% |
| Heparin | 5% | 2% |
| | 3% | 1% |
| | 3% | 1% |
| Cyclosporine A | 2% | 0% |
| Antiandrogen | 2% | 0% |
| Cholestyramine | 0% | 0% |
Note: *Possible multiple medications per patient: percentages do not total 100; n = 4,919; sourced from VistA with calculations from the authors.